TAK-242 in Patients With Acute Alcoholic Hepatitis

Summary

A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in subjects with acute decompensation of alcohol-related cirrhosis due to alcoholic hepatitis resulting in acute-on-chronic liver failure.

Timeline

Start

2021-12

Primary completion

2022-12

Completion

2022-12

Drugs

Indications